
Sign up to save your podcasts
Or


Send us Fan Mail
This week on the podcast I interview Jacob Glanville, PhD we discuss Jacob's journey that led him to Distributed Bio then to Centivax and his work on the Netflix show Pandemic. Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.
By Don Davis PhD, MBA5
1010 ratings
Send us Fan Mail
This week on the podcast I interview Jacob Glanville, PhD we discuss Jacob's journey that led him to Distributed Bio then to Centivax and his work on the Netflix show Pandemic. Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.

770 Listeners

822 Listeners

6,313 Listeners

29,305 Listeners

20 Listeners

19,731 Listeners

1,324 Listeners